About Marinomed

Marinomed develops and markets via partnerships products against respiratory diseases using its innovative antiviral respiratory technology platform, MAVIREX© and its novel drug delivery technology MARINOSOLV®. Marinomed is located in Vienna, Austria and was founded in 2006 as a spin-off from the Veterinary University of Vienna.

 

GET TO KNOW US

THIS IS WHO WE ARE

Marinomed Biotechnologie GmbH is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary MAVIREX© platform are marketed with renowned partners in a growing number of countries around the globe.

The new MARINOSOLV® platform enables novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, allowing a faster onset of action and a better bioavailability. The MARINOSOLV® technology is not limited to a specific compound and has the potential to facilitate delivery of any compound with solubility issues.

Marinomed Biotechnologie GmbH is a spin-off from the Veterinary University Vienna and is located in Vienna, Austria.